Epidemiology and Clinical Impact of Sickle Cell Disease in India: Genetic Diversity, Regional Inequities, And Contemporary Management Approaches - A Review

References

[1] Babu BV, Sharma Y, Surti SB, Bhat D, Sridevi P, Ranjit M, Sudhakar G, Sarmah J. Indian sickle cell disease registry for surveillance and patient management: Development and implementation. Int J Health Plann Manage. 2023;38(5):1483-1494. https://

[2] Babu BV, Sridevi P, Surti SB, Bhat D, Sarmah J, Sudhakar G, Sharma Y. Sickle cell disease-related knowledge and perceptions of traditional healers in tribal communities in India: implications on sickle cell disease programme. J Community Genet. 2022;13(6):597-603. https://

[3] Balgir RS, Dash BP, Murmu B. Interaction of G6PD deficiency with sickle cell disease in India. J Assoc Physicians India. 2020;68(2):52-56.

[4] Budhbaware T, Rathored J. Sickle Cell Disease at a Tertiary Care Center in the Vidarbha Region of India: Protocol for a Clinical and Observational Study. JMIR Res Protoc. 2026;15:e80483. https://

[5] Colah R, Italia K, Gorakshakar A. Burden of sickle cell disease in India: The challenges ahead. Indian J Med Res. 2020; 151(5):429- 431.

[6] Colah R, Mukherjee M, Ghosh K. Sickle cell disease in India. Curr Opin Hematol. 2014;21(3):215-23. https:// 029.

[7] Colah RB, Italia K, Gorakshakar AC. Challenges in the control of sickle cell disease in India. Indian J Med Res. 2020;151(1):1-7.

[8] Colah RB, Mukherjee MB, Martin S, Ghosh K. Sickle cell disease in tribal populations in India. Indian J Med Res. 2015;141(5):509-15. https://

[9] Deshpande SV, Bhatwadekar SS, Desai P, Bhavsar T, Patel A, Koranne A, Mehta A, Khadse S. Hydroxyurea in Sickle Cell Disease: Our Experience in Western India. Indian J Hematol Blood Transfus. 2016;32(2):215-20. https://

[10] Elendu C, Amaechi DC, Alakwe-Ojimba CE, Elendu TC, Elendu RC, Ayabazu CP, Aina TO, Aborisade O, Adenikinju JS. Understanding Sickle cell disease: Causes, symptoms, and treatment options. Medicine (Baltimore). 2023;102(38):e35237. https:// 37.

[11] Fasola FA, Fowodu FO, Shokunbi WA, Kotila TR. The effect of the coinheritance of Glucose-6-phosphate dehydrogenase deficiency on the severity of sickle cell disease. Niger Postgrad Med J. 2019;26(2):118-122. https://

[12] Gupta K, Krishnamurti L, Jain D. Sickle cell disease in India: the journey and hope for the future. Hematology Am Soc Hematol Educ Program. 2024;2024(1):1 -9. https:// 78.

[13] Hockham C, Bhatt S, Colah R, Mukherjee MB, Penman BS, Gupta S, Piel FB. The spatial epidemiology of sickle-cell anaemia in India. Sci Rep. 2018;8(1):17685. https://

[14] Italia K, Jain D, Gattani S, Jijina F, Nadkarni A, Sawant P, Nair S, Mohanty D, Ghosh K, Colah R. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype. Blood Cells Mol Dis. 2009;42(1):25-31. https://

[15] Italia MB, Kirolos S. Sickle cell disease in anaemic children in a Sierra Leonean district hospital: a case series. Oxf Med Case Reports. 2019;(7):omz061. https://

[16] Jain D, Gupta M, Madkaikar M, Jena RK, Khargekar N, Saraf SL, Krishnamurti L, Gupta K. Sickle cell disease in India: current status and progress. Lancet Haematol. 2024;11(5):e322-e323. https:// 3026(24)00109-1.

[17] Jain D, Sarvaiya D, Mehta S, Mohanasundaram S, Gogtay J. The Indian experience with hydroxyurea in sickle cell disease: A 25-year systematic review. Indian J Med Res. 2025;162(1):28 -43. https://

[18] Jonani B, Kasule EC, Herman BR, Arturo JF, Mugambwa MC, Stephen S, Mundaka JB, Kwizera R, Mboowa G, Bongomin F. Burden of sickle cell anemia in Africa: A systematic review and meta-analysis. PLoS One. 2025;20(11):e0337090. https://

[19] Kanter J, Smith WR, Desai PC, Treadwell M, Andemariam B, Little J, Nugent D, Claster S, Manwani DG, Baker J, Strouse JJ, Osunkwo I, Stewart RW, King A, Shook LM, Roberts JD, Lanzkron S. Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects. Blood Adv. 2020;4(16):3804 -3813. https:// 1743.

[20] Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, Smith WR, Panepinto JA, Weatherall DJ, Costa FF, Vichinsky EP. Sickle cell disease. Nat Rev Dis Primers. 2018;4:18010. https://

[21] Kinney TR, Sleeper LA, Wang WC, Zimmerman RA, Pegelow CH, Ohene - Frempong K, Wethers DL, Bello JA, Vichinsky EP, Moser FG, Gallagher DM, DeBaun MR, Platt OS, Miller ST. Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. The Cooperative Study of Sickle Cell Disease. Pediatrics. 1999;103(3):640-5. https://

[22] Kochhar M, McGann PT. Sickle cell disease in India: Not just a mild condition. Br J Haematol. 2025;206(1):380 -381. https://

[23] Makani J, Sangeda RZ, Nnodu O, Nembaware V, Osei-Akoto A, Paintsil V, Balandya E, Kent J, Luzzatto L, Ofori-Acquah S, Olopade OI, Pallangyo K, Minja IK, Jonas M, Mazandu GK, Mulder N, Ohene-Frempong K, Wonkam A. SickleInAfrica. Lancet Haematol. 2020;7(2):e98-e99. https:// 3026(20)30006-5.

[24] Ministry of Health and Family Welfare, Government of India. National Sickle Cell Anaemia Elimination Mission: Operational Guidelines. New Delhi; 2023.

[25] Mukherjee MB, Surve RR, Ghosh K, Colah RB, Mohanty D. Clinical diversity of sickle cell disease in western india - influence of genetic factors. Acta Haematol. 2000;103(2):122-3. https://

[26] National Sickle Cell Anaemia Elimination Mission data, India Ministry of Health, 2025.

[27] Obeagu EI, John A. Health equity in sickle cell disease: overcoming barriers to care in marginalized communities. Ann Med Surg (Lond). 2025;87(12):8610 -8616. https:// 95.

[28] Obeagu EI, Obeagu GU. Malnutrition in sickle cell anemia: Prevalence, impact, and interventions: A Review. Medicine (Baltimore). 2024;103(20):e38164. https:// 64.

[29] Obed SA, Asah-Opoku K, Aboagye S, Torto M, Oppong SA, Nuamah MA. Awareness of Sickle Cell Trait Status: A Cross-Sectional Survey of Antenatal Women in Ghana. Am J Trop Med Hyg. 2017;96(3):735 -740. https://

[30] Panda PC, Mishra NR, Patra CS, Nayak BK, Panda SK. Intravenous Acetaminophen vs Intravenous Diclofenac Sodium in Management of Skeletal Vaso-occlusive Crisis Among Children with Homozygous Sickle Cell Disease: A Randomized Controlled Trial. Indian Pediatr. 2021;58(3):229-232.

[31] Patel DK, Mashon RS, Patel S, Das BS, Purohit P, Bishwal SC. Low dose hydroxyurea is effective in reducing the incidence of painful crisis and frequency of blood transfusion in sickle cell anemia patients from eastern India. Hemoglobin. 2012;36(5):409- 20. https:// 7.

[32] Patel J, Serjeant GR. Newborn screening for sickle cell disease in India: the need for defining optimal clinical care. Indian J Pediatr. 2014;81(3):229 -30. https://

[33] Piel FB, Rees DC, DeBaun MR, Nnodu O, Ranque B et al.,. Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission. Lancet Haematol. 2023;10(8):e633 -e686. https:// 3026(23)00096-0.

[34] Piel FB, Steinberg MH, Rees DC. Sickle cell disease. Lancet. 2021;397(10283):1486-1498.

[35] Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. N Engl J Med. 2017;376(16):1561- 1573. https://

[36] Rao SS, Ghosh K, Mohanty D. Sickle cell disease in tribal populations of India. Indian J Med Res. 2009;130(5):533-540.

[37] Rees DC, Williams TN, Gladwin MT. Sickle- cell disease. Lancet. 2010;376(9757):2018-31. https:// 6736(10)61029-X.

[38] Serjeant GR, Ghosh K, Patel J. Sickle cell disease in India: A perspective. Indian J Med Res. 2016;143(1):21 -24. https://

[39] Serjeant GR. The natural history of sickle cell disease. Cold Spring Harb Perspect Med. 2013;3(10):a011783. https://

[40] Shivwanshi LR, Singh E, Kumar A. A positive correlation between sickle cell anemia and g6pd deficiency from population of Chhattisgarh, India. Gene. 2019;707:143-150. https://

[41] Singh S, Patra PK, Kar R. Sickle cell disease in tribal populations of southern Rajasthan. Indian J Med Res. 2018;148(4):421-426.

[42] Smith WR, Scherer M. Sickle-cell pain: advances in epidemiology and etiology. Hematology Am Soc Hematol Educ Program. 2010;2010:409-15. https:// 2010.1.409.

[43] Thein SL. Genetic modifiers of sickle cell disease. Hemoglobin. 2011;35(5-6):589-606. https:// 6.

[44] Tubman VN, Makani J. Turf wars: exploring splenomegaly in sickle cell disease in malaria- endemic regions. Br J Haematol. 2017;177(6):938-946. https://

[45] Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet. 2017;390(10091):311-323. https:// 6736(17)30193-9.

[46] Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ. 2001;79(8):704-12.

[47] Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood. 2010;115(22):4331-6. https:// 251348. VI. TABLE LEGENDS Table 1 Geographic Distribution of Sickle Cell Disease (SCD) and Sickle Cell Trait (SCT) in India Table 2 Genetic Modifiers Influencing the Phenotype of Sickle Cell Disease in Indian Populations Table 3 Major Clinical Complications Observed in Indian Sickle Cell Disease (SCD) Cohorts Graphical abstract Table 1 Geographic Distribution of Sickle Cell Disease (SCD) and Sickle Cell Trait (SCT) in India S. No Region / Study Population stidied HbS Carrier (SCT) (%) SCD (HbSS) (%) Indian Evidence/Notes Reference 1 Odisha state (screening, 2025) Tribal and non- tribal communities 8-17 ~1.7 Highest registered SCD burden nationally; extensive mass screening under state programs Times of India, 2025, Colah et al., 2025. 2 Madhya Pradesh (Central India) Gonds, Bhils, rural populations 10–33 0.8-1.9 High tribal concentration; early childhood detection common Colah et al., 2015, Balgir et al., 2020. 3 Gujarat (Western India) Tribal belts (Bhils, Rathwas 6-18 0.5-1.5 Long-standing community screening initiatives; significant SCT prevalence Times of India, 2025, Colah et al., 2015. 4 Chhattisgarh Scheduled Tribes 10-33 1.0-2.0 High HbS frequency linked to malaria-endemic ecology Shrikhande et al., 2007; Balgir et al., 2020. 5 Maharashtra (Vidarbha region) Mixed tribal– rural populations 5-14 0.6-1.4 School- and antenatal-based screening identifies both SCT and HbSS Kamble and Chaturvedi, 2000. 6 Rajasthan (Southern districts) Garasia and Bhil tribes 9-16 0.7–1.6 Marked intra -tribal variation in prevalence Singh et al., 2018. 7 Jharkhand Tribal populations 5–10 0.3–0.9 Moderate prevalence; limited registry coverage Balgir et al., 2020 8 Andhra Pradesh / Telangana Scheduled Tribes 4-12 0.3–1.0 Regional heterogeneity with clustered tribal burden Rao et al., 2009. 9 Urban migrant cohorts Mixed ethnic groups 1-4 <0.5 Increasing detection due to rural–urban migration Piel et al., 2021. 10 North & North- East India General population <1 Rare Low reported prevalence; under-screening possible Colah et al., 2015. Table 2 Genetic Modifiers Influencing the Phenotype of Sickle Cell Disease in Indian Populations S. No Genetic Modifier / Variable Frequency / Burden in India Indian Description Evidence / Notes Reference 1 Arab–Indian HbS haplotype Predominant (>85%) Characteristic Indian HbS background Associated with relatively higher HbF and delayed complications Mukherjee et al., 2010; Colah et al., 2020. 2 Elevated fetal hemoglobin (HbF) Common (8– 20%) Seen in many Indian HbSS patients Modulates disease severity and reduces VOC frequency Thein 2013. 3 α-Thalassemia co- inheritance 30–60% in tribal belts Frequent deletional α- thalassemia Reduces hemolysis but may increase blood viscosity Mukherjee et al., 2010; Italia et al., 2020. 4 β-Thalassemia co-Region-specific Sβ⁰/Sβ⁺ genotypes Increases anemia Colah et al., 2020 Table 3 Major Clinical Complications Observed in Indian Sickle Cell Disease (SCD) Cohorts S. N o Complicatio n / Variable Frequency / Burden in India Indian Context Impact on Disease Description Evidence / Notes Referenc e 1 Chronic hemolytic anemia Universal All age groups Baseline morbidity Persistent anemia due to red cell destruction Leading cause of hospitalizati on Rees et al., 2010; Colah et al., 2020. 2 Vaso- occlusive crises (VOC) Very common Children and adults Major morbidity driver Painful ischemic episodes affecting bones/chest Leading cause of hospitalizati on Ware et al., 2017; Jain et al., 2012. inheritance reported severity and transfusion need 5 HbD Punjab interaction Low–moderate (NW India) Compound heterozygosity (HbSD) Produces variable clinical severity Gorakshakar and Colah 2009 5 G6PD deficiency 5–20% in tribal groups X-linked enzymopathy Increases hemolysis and neonatal jaundice risk Balgir et al., 2020; Jain et a., 2022. 6 BCL11A polymorphisms Moderate HbF regulatory gene variants Associated with HbF persistence Lettre et al., 2008. 7 HBS1L–MYB intergenic variants Moderate Erythropoietic regulator Influences anemia severity Thein 2013. 8 XmnI polymorphism (γ- globin) Common Promoter variant of HBG2 Linked with higher HbF expression Mukherjee et al., 2010. 9 Iron deficiency coexistence High in women/children Nutritional modifier Worsens anemia independent of genotype Pasricha et al., 2010. 10 Malaria exposure Endemic regions Historical selective pressure Explains high HbS frequencies Balgir et al., 2020 11 Epigenetic regulation Emerging evidence DNA methylation effects Potential target for novel therapies Lettre et al., 2008. 12 Red cell dehydration pathways Variable Ion channel dysregulation Contributes to VOC risk Rees et al., 2010. 13 Genetic heterogeneity High Multiple interacting modifiers Limits phenotype prediction Piel et al., 2021. 14 Need for molecular profiling Increasing Precision medicine approach Essential for individualized care Kanter et al., 2021 3 Acute chest syndrome (ACS) Moderate Often underdiagnosed High mortality risk Pulmonary infiltrates with fever/hypoxia Requires early intervention Vichinsk y et al., 2000. 4 Severe infections High in childhood Tribal and rural settings Major cause of death Functional asplenia- related susceptibility Vaccination gaps worsen outcomes Booth et al., 2010; Colah et al., 2020. 5 Functional asplenia Common Early childhood onset Infection risk Loss of splenic immune function Underpins sepsis risk Rees et al., 2010 6 Stroke (overt/silent ) Low– moderate Increasing recognition Long-term disability Cerebrovascul ar occlusion Often under- screened DeBaun et al., 2016. 7 Avascular necrosis Moderate Adolescents/adul ts Chronic disability Bone ischemia, hip involvement Limits mobility Jain et al., 2012; Ware et al., 2017 8 Pulmonary hypertensio n Underreport ed Adults Reduced survival Chronic hemolysis- related vasculopathy Needs systematic screening Gladwin and Sachdev 2012. 9 Renal dysfunction Progressive Adolescents/adul ts Chronic morbidity Proteinuria, CKD Late diagnosis common Nath and Hebbel 2015. 10 Gallstone disease Common Adults Surgical burden Pigment stones from hemolysis Frequently incidental Rees et al., 2010 11 Growth retardation Moderate Pediatric cohorts Development al impact Chronic anemia/nutriti on deficit More severe in rural areas Pasricha et al., 2010. 12 Chronic pain syndromes Common Adolescents/adul ts QoL reduction Persistent nociceptive pain Psychosocial impact Smith and Scherer 2010. 13 Leg ulcers Low– moderate Adults Chronic morbidity Vascular insufficiency Poor wound healing Minniti et al., 2010. 14 Priapism Low Males Urologic morbidity Painful prolonged erection Underreporte d Burnett et al., 2012. 15 Pregnancy complicatio ns Moderate Women with SCD Maternal– fetal risk Preterm birth, anemia Needs specialized care Boafor et al., 2016.

@article{1722238,
      author = {Venkataswamy Mallepogu, Nagalakshmamma Vadabingi, Balaji Meriga},
      title = {Epidemiology and Clinical Impact of Sickle Cell Disease in India: Genetic Diversity, Regional Inequities, And Contemporary Management Approaches - A Review},
      journal = {Iconic Research And Engineering Journals},
      year = {2026},
      volume = {10},
      number = {2},
      pages = {1024-1038},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1722238.pdf},
      abstract = {Sickle cell disease (SCD) is a hereditary hemoglobinopathy caused by a β-globin gene mutation leading to hemoglobin S polymerization, chronic hemolytic anemia, vaso-occlusion, and progressive multi-organ damage. India represents one of the largest global contributors to SCD burden, with pronounced geographic, ethnic, and socioeconomic heterogeneity, particularly affecting tribal and marginalized populations. This review aims to synthesize contemporary evidence on the epidemiology, genetic modifiers, clinical spectrum, and public health response to SCD in India, highlighting key disparities, challenges, and opportunities for disease control. A structured narrative review was conducted using peer-reviewed literature retrieved from PubMed, Science Direct, and allied databases, supplemented by government reports and national program documents. Studies published between 2000 and 2025 reporting epidemiologic, genetic, clinical, or therapeutic data on Indian SCD populations were included. Evidence was thematically synthesized, with findings summarized across geographic distribution, genetic modifiers, and clinical outcomes. India has over 215,000 confirmed SCD cases, with the highest burden concentrated in central, western, and eastern states, particularly among Scheduled Tribes and vulnerable communities. SCD in India is predominantly associated with the Arab–Indian haplotype, often linked to higher fetal hemoglobin levels, yet substantial phenotypic heterogeneity exists due to co-inheritance of α- and β-thalassemia, G6PD deficiency, nutritional factors, and environmental influences. Patients experience a wide spectrum of acute and chronic complications, including vaso-occlusive crises, infections, acute chest syndrome, and progressive organ damage. Expanded screening programs and hydroxyurea therapy have improved detection and outcomes, though gaps in access and continuity of care persist. SCD in India remains a major public health challenge characterized by marked regional and genetic diversity. Strengthening universal screening, integrating genotype-informed care, and reinforcing primary healthcare and national initiatives are essential to reduce morbidity and mortality and achieve sustainable disease control.},
      keywords = {Sickle Cell Disease, India, Epidemiology, Genetics, Tribal Health, Hydroxyurea Therapy},
      month = {August},
      doi = {https://doi.org/10.64388/IREV10I2-1722238}
  }